Abstract 162P
Background
Radiomics has emerged as a potential tool to predict clinical outcomes in prostate cancer (Pca ). MRI has a fundamental role in staging and radiotherapy planning, being affected in the case of receiving prior androgen deprivation treatment (ADT). The aim of this study was to determine imaging biomarker profiles that allow to identify patients with a worse prognosis and a higher risk of biochemical relapse (BQR).
Methods
A single-center, retrospective, observational study was designed. Baseline MRIs (T2w, DWI and/or DCE sequences) from PCa patients treated with ADT and radiotherapy were included. Using Quibim’s QP-Prostate ® solution, subregions (Transition + Central Zone [TZ + CZ], Peripheral zone [PZ] and seminal vesicles [SV]) were automatically segmented. For each subregion and for the whole prostate (WP), computed using the weighted biomarkers averaging, 105 radiomic features (shape and textures) from T2w, apparent diffusion coefficient (ADC) variables from DWI and perfusion parameters from DCE were extracted.
Results
A total of 128 T2w, 107 DWI and 62 DCE MRIs from 128 PCa patients (32 [25%] low or favourable intermediate risk [group 1] and 96 (75%) high or unfavourable intermediate risk [group 2]) were included, of whom 20 (16%) experienced BQR (18 [19%] from group 2). According to risk stratification, patients from group 1 presented more homogeneous textures in PZ and WP than group 2. Regarding BQR, the ADC mean was higher in the TZ in those who did not relapse, while patients with greater major axis length in the PZ, WP and SV were more likely to relapse. In SV and WP heterogenicity-related feature values were significantly higher in BQR. In group 2, diffusion parameters and shape variables in the SV were significantly different in those experiencing BQR.
Conclusions
Imaging biomarker profiles in this PCa population may help to better stratify patients at risk based on baseline MRIs. High-risk patients may be identified by the heterogeneity of textures. Diffusion and texture parameters may determine a higher probability of relapse.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01